Abstract
Fluconazole 50 mg daily for 14-28 days was effective in the treatment of patients with AIDS and AIDS-related complex with severe oropharyngeal and oesophageal candidiasis. Of 24 patients entered, 17 (81%), including seven with oesophageal candidiasis, were clinically cured and two (9.5%) improved at the end of treatment. Following clinical cure, 14 patients were entered into the double-blind phase of the study, where fluconazole (150 mg) or placebo capsules were given once weekly. Treatment was double blind. Fluconazole 150 mg once weekly was found to be effective in maintaining patients both clinically and mycologically free of oropharyngeal candidiasis.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
AIDS-Related Complex / complications*
-
Acquired Immunodeficiency Syndrome / complications*
-
Adult
-
Candidiasis, Oral / complications
-
Candidiasis, Oral / drug therapy*
-
Candidiasis, Oral / prevention & control
-
Clinical Trials as Topic
-
Double-Blind Method
-
Esophageal Neoplasms / complications
-
Esophageal Neoplasms / drug therapy
-
Esophageal Neoplasms / prevention & control
-
Fluconazole / therapeutic use*
-
Humans
-
Male
-
Middle Aged
-
Pharyngeal Diseases / complications
-
Pharyngeal Diseases / drug therapy*
-
Pharyngeal Diseases / prevention & control
-
Recurrence
-
Remission Induction
-
Risk Factors
-
Time Factors